Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Porcine , Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Recombinant protein corresponding to A-subunit of coagulation Factor XIII|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11751 targets Factor XIII A in IHC (P) and WB applications and shows reactivity with Human samples.
The MA5-11751 immunogen is recombinant protein corresponding to A-subunit of coagulation Factor XIII.
Factor XIII in both reduced and non-reduced forms. It does not react with human Factor XIII B-chain or human Factor XII. Factor XIII is a beta-globulin found in plasma and is composed of two subunits. Factor XIII-A is the catalytic subunit and is a dimer of M.W. 160kDa. Factor XIII is present in plasma as an alpha2beta2 heterodimer (M.W. 320kDa); whereas in platelets, only the alpha2 unit exists. Factor XIIIa is a dermal dendrocyte marker and shows variable reaction with these types of tumors. It can be used for histiocytic phenotyping and has been reported to mark capillary hemangiomas and tumors of the central nervous system. Factor XIII has also been used with CD34 to differentiate between dermatofibroma and dermatofibrosarcoma protuberans.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Procoagulant platelets form an α-granule protein-covered "cap" on their surface that promotes their attachment to aggregates.
MA5-11751 was used in western blot to study the role of the alpha-granule-containing cap structure of pro-coagulant platelets in their ability to attach to aggregates
|Abaeva AA,Canault M,Kotova YN,Obydennyy SI,Yakimenko AO,Podoplelova NA,Kolyadko VN,Chambost H,Mazurov AV,Ataullakhanov FI,Nurden AT,Alessi MC,Panteleev MA||The Journal of biological chemistry (288:29621)||2013|
Malignant dermatofibroma: clinicopathological, immunohistochemical, and molecular analysis of seven cases.
MA5-11751 was used in immunohistochemistry to report on seven cases of malignant dermatofibroma
|Mentzel T,Wiesner T,Cerroni L,Hantschke M,Kutzner H,Rütten A,Häberle M,Bisceglia M,Chibon F,Coindre JM||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (26:256)||2013|
Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans.
MA5-11751 was used in immunohistochemistry to characterize the plaque-like CD34-positive dermal fibroma
|Kutzner H,Mentzel T,Palmedo G,Hantschke M,Rütten A,Paredes BE,Schärer L,Guillen CS,Requena L||The American journal of surgical pathology (34:190)||2010|
Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent.
MA5-11751 was used in immunohistochemistry to investigate the effectiveness of a novel MRI contrast agent for the analysis of early thrombus formation
|Miserus RJ,Herías MV,Prinzen L,Lobbes MB,Van Suylen RJ,Dirksen A,Hackeng TM,Heemskerk JW,van Engelshoven JM,Daemen MJ,van Zandvoort MA,Heeneman S,Kooi ME||JACC. Cardiovascular imaging (2:987)||2009|
Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA.
MA5-11751 was used in immunohistochemistry to study transglutaminase-2 as a marker of chondrocyte hypertrophy and disease severity in a model of osteoarthritis
|Huebner JL,Johnson KA,Kraus VB,Terkeltaub RA||Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society (17:1056)||2009|
Dermatomyofibroma: clinicopathologic and immunohistochemical analysis of 56 cases and reappraisal of a rare and distinct cutaneous neoplasm.
MA5-11751 was used in immunohistochemistry to investigate clinicopathologic spectrum of dermatomyofibroma
|Mentzel T,Kutzner H||The American Journal of dermatopathology (31:44)||2009|
Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages.
MA5-11751 was used in immunohistochemistry to study CD11c+BDCA-1+ dendritic cell and CD163+FXIIIA+ macrophage populations in human dermis
|Zaba LC,Fuentes-Duculan J,Steinman RM,Krueger JG,Lowes MA||The Journal of clinical investigation (117:2517)||2007|
Incidental calcifying fibrous tumor of the stomach presenting as a polyp.
MA5-11751 was used in immunohistochemistry to report on a case of incidental calcifying fibrous tumor of the stomach presenting as a polyp
|Elpek GO,Küpesiz GY,Ogüs M||Pathology international (56:227)||2006|
The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha.
MA5-11751 was used in immunohistochemistry to investigate the expression of receptor for advanced glycation end products and its regulatary mechanism in skin
|Lohwasser C,Neureiter D,Weigle B,Kirchner T,Schuppan D||The Journal of investigative dermatology (126:291)||2006|
FSF, A subunit, TGase, bA525O21.1 (coagulation factor XIII, A1 polypeptide), coagulation factor XIII A chain, coagulation factor XIII, A polypeptide, coagulation factor XIIIa, factor XIIIa, fibrin stabilizing factor, A subunit, fibrinoligase, protein-glutamine gamma-glutamyltransferase A chain, transglutaminase A chain, transglutaminase. plasma, FSF, A subunit, bA525O21.1 (coagulation factor XIII, A1 polypeptide), coagulation factor XIII, A polypeptide, fibrin stabilizing factor